CommentaryJournal of Pharmacology and PharmacotherapeuticsVol. 5 | Issue 1 | 2014 | pp. 8–9Open access
Dextropropoxyphene ban in India: Is there a case for reconsideration?
- 1*
- 1 Department of Psychiatry, National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Yatan Pal Singh Balhara
Department of Psychiatry, National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India.
Email: ypsbalhara@gmail.com
Copyright: © 2014 Manuscript Technomedia LLP. This is an open access article.
- Published:
- Jan 1, 2014
How to cite
Balhara, Y. P. S. (2014). Dextropropoxyphene ban in India: Is there a case for reconsideration? Journal of Pharmacology and Pharmacotherapeutics, 5(1), 8–9. https://doi.org/10.4103/0976-500X.124406
Abstract
Dextropropoxyphene is a synthetic weak opioid used as analgesic both as standalone as well as in combination with acetaminophen for more than 50 years. Ministry of Health and Family Welfare, Government of India has issued a gazette notification (dated May 23, 2013) suspending the manufacture, sale, and distribution of dextropropoxyphene and formulations containing dextropropoxyphene in the country. This suspension has led to debate about the reasons behind this decision and its implications. India is not the first country to withdraw dextropropoxyphene as it has already been withdrawn from various countries including Australia, Canada, European Union, New Zealand, UK, and USA. UK was probably the first to issue a notification regarding its withdrawal in January 2005. Later on it was withdrawn across the European Union in 2009. Subsequently, recommendations against its use were issued by the US Food and Drug Administration (FDA), New Zealand, and Canada in the year 2010. Australia issued a notification recommending against its use in 2012. All preparation containing dextropropoxyphene (including combinations with acetaminophen) have been withdrawn in these countries. Notably the withdrawal of dextropropoxyphene/acetaminophen combination containing preparations in Australia has been withheld pending a review sought by a pharmaceutical company in the court.
Subject
Article metadata
| Title | Dextropropoxyphene ban in India: Is there a case for reconsideration? |
|---|---|
| Authors | Yatan Pal Singh Balhara |
| Affiliations | Department of Psychiatry, National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India. |
| Corresponding author | ypsbalhara@gmail.com |
| Journal | Journal of Pharmacology and Pharmacotherapeutics |
| Volume / Issue | Vol. 5, Issue 1 (2014) |
Also in this issue
Readers Also Viewed
Effect of the Fractions of Coccinia grandis on Ethanol- Induced Cerebral Oxidative Stress in Rats
M. Umamaheswari, T. K. Chatterjee
Jan 1, 2009
Phytochemical Screening and Antioxidant Activity Evaluation of Selected Philippine Fruit Peels and Pulps
Mildred Dagcuta Pates, Angelo Mark Po Walag, Romeo M. Del Rosario
Aug 17, 2026
Impact of Artificial Intelligence Assisted Drug Therapy Optimization on Drug Related Problems Amongst Older Adult Patients: A Systematic Review
Jehath Syed, Christy Thomas, Bavneet Kaur
Oct 23, 2026